KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Work In Process (2018 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Work In Process for 8 consecutive years, with $65.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Work In Process changed 0.22% year-over-year to $65.1 million, compared with a TTM value of $65.1 million through Dec 2025, changed 0.22%, and an annual FY2025 reading of $65.1 million, changed 0.22% over the prior year.
  • Work In Process was $65.1 million for Q4 2025 at Alnylam Pharmaceuticals, up from $35.5 million in the prior quarter.
  • Across five years, Work In Process topped out at $116.7 million in Q2 2023 and bottomed at $23.6 million in Q1 2021.
  • Average Work In Process over 5 years is $73.0 million, with a median of $73.0 million recorded in 2024.
  • The sharpest move saw Work In Process soared 525.07% in 2021, then tumbled 49.18% in 2025.
  • Year by year, Work In Process stood at $100.9 million in 2021, then grew by 12.72% to $113.8 million in 2022, then crashed by 32.36% to $77.0 million in 2023, then fell by 15.57% to $65.0 million in 2024, then rose by 0.22% to $65.1 million in 2025.
  • Business Quant data shows Work In Process for ALNY at $65.1 million in Q4 2025, $35.5 million in Q3 2025, and $43.8 million in Q2 2025.